Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326

Benzinga Newsdesk www.benzinga.com Positive 69.8%

Neg 0% Neu 0% Pos 69.8%

Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.